Form S-8 C4 Therapeutics, Inc.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Form S-8 C4 Therapeutics, Inc.

Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'

February 24, 2023 1:24 PM EST

Credit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 (from $12.00).

The analyst comments "CCCC reported 4Q22 financial results on Thursday morning with GAAP EPS of -$0.65. Total collaboration revenues... More